Med (6 weeks after removal). The measure of pain was gauged using the visual analogue pain scale (VAS), a range of 0?0. The numbers 0, 2, 4, 6, 8 and 10 are accompanied by face drawings that correspond to the numbers, the participant selects one that best represents how they feel. These scores were captured during four different stages of the study: during placement, post placement, during removal and post removal, at both scheduled and unscheduled visits. Follow up included a phone call on day 1 after placement, a scheduled visit on day 5? for removal and on day 14, with a further phone call. The phone calls were made by trained nurses and counselors. A 24-hour hotline team was available for unscheduled visits and calls. The clients who were unscheduled were attended to by trained nurses, the principal investigator and or designated co principal investigator.Methods Study designOne-arm, open label, prospective study to verify the safety of the non-surgical PrePexTM device for adult male circumcision with no injected anesthesia, performed by physicians (general surgeons and medical officers) and non physician clinicians (clinical officers and nurses).Study settingThis study was conducted from August to October 2012 at an urban SMC site at International Hospital Kampala (IHK), a private facility in Uganda’s capital. The population of Kampala by day is estimated to be 2.5 illion people [12].Study populationAll males were scheduled to undergo voluntary circumcision in an effort to prevent the spread of HIV in resource limited high prevalence settings. No marketing or demand creation activities for PrePex were done. In the past 18 months the majority of clients presenting for SMC came from within 10km proximity of the IHK SMC site.Study durationStudy duration per subject was up to 8 weeks (including follow up). The follow up was conducted by telephone, face-to-face scheduled visits and unscheduled visits if necessary, as judged by the patient or the Principal Investigator.Inclusion criteriaParticipants included were those: aged ?8 to 49 years, eligible adult males wishing to be circumcised, agreed to abstain from sexual intercourse for 6 weeks after device removal, agreed to abstain from masturbation for 2 weeks after device removal, agreed to perform follow up via telephone (or physical review if applicable) and those who were able to comprehend and freely give informed written consent for participation in this study and were Ensartinib site considered by the investigators to have good compliance for the study.Exclusion criteriaSubjects excluded were those: with active genital infection, (e.g. genital ulcers, urethral discharges), and those with penile abnormalities deemed unfit for device placement such as frenulum breve, Necrostatin-1 price hypospadias, phimosis, paraphimosis, warts under the prepuce and epispadias. Those known to have bleeding or coagulation abnormalities; other co-morbidities such as hypertension, uncontrolled diabetes, mental illnesses and those whose prepucial openings could not accommodate the inner plastic ring were also excluded.Data collectionA pretested structured Case Report Form (CRF) was used to collect data. The questionnaires were filled in by research attendants and all designated and trained device operators. Data was collected at placement, removal and follow up for allPLOS ONE | www.plosone.orgAdverse Events of PrePex in Ugandan Urban Settingclients. In addition, 300 participants were interviewed after removal to gather information on odo.Med (6 weeks after removal). The measure of pain was gauged using the visual analogue pain scale (VAS), a range of 0?0. The numbers 0, 2, 4, 6, 8 and 10 are accompanied by face drawings that correspond to the numbers, the participant selects one that best represents how they feel. These scores were captured during four different stages of the study: during placement, post placement, during removal and post removal, at both scheduled and unscheduled visits. Follow up included a phone call on day 1 after placement, a scheduled visit on day 5? for removal and on day 14, with a further phone call. The phone calls were made by trained nurses and counselors. A 24-hour hotline team was available for unscheduled visits and calls. The clients who were unscheduled were attended to by trained nurses, the principal investigator and or designated co principal investigator.Methods Study designOne-arm, open label, prospective study to verify the safety of the non-surgical PrePexTM device for adult male circumcision with no injected anesthesia, performed by physicians (general surgeons and medical officers) and non physician clinicians (clinical officers and nurses).Study settingThis study was conducted from August to October 2012 at an urban SMC site at International Hospital Kampala (IHK), a private facility in Uganda’s capital. The population of Kampala by day is estimated to be 2.5 illion people [12].Study populationAll males were scheduled to undergo voluntary circumcision in an effort to prevent the spread of HIV in resource limited high prevalence settings. No marketing or demand creation activities for PrePex were done. In the past 18 months the majority of clients presenting for SMC came from within 10km proximity of the IHK SMC site.Study durationStudy duration per subject was up to 8 weeks (including follow up). The follow up was conducted by telephone, face-to-face scheduled visits and unscheduled visits if necessary, as judged by the patient or the Principal Investigator.Inclusion criteriaParticipants included were those: aged ?8 to 49 years, eligible adult males wishing to be circumcised, agreed to abstain from sexual intercourse for 6 weeks after device removal, agreed to abstain from masturbation for 2 weeks after device removal, agreed to perform follow up via telephone (or physical review if applicable) and those who were able to comprehend and freely give informed written consent for participation in this study and were considered by the investigators to have good compliance for the study.Exclusion criteriaSubjects excluded were those: with active genital infection, (e.g. genital ulcers, urethral discharges), and those with penile abnormalities deemed unfit for device placement such as frenulum breve, hypospadias, phimosis, paraphimosis, warts under the prepuce and epispadias. Those known to have bleeding or coagulation abnormalities; other co-morbidities such as hypertension, uncontrolled diabetes, mental illnesses and those whose prepucial openings could not accommodate the inner plastic ring were also excluded.Data collectionA pretested structured Case Report Form (CRF) was used to collect data. The questionnaires were filled in by research attendants and all designated and trained device operators. Data was collected at placement, removal and follow up for allPLOS ONE | www.plosone.orgAdverse Events of PrePex in Ugandan Urban Settingclients. In addition, 300 participants were interviewed after removal to gather information on odo.
